Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 18/20 | 0.70 |
| ▸ | ITGA4 | P13612 | 18/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL2128631 | 0.99 | ITGB1 (0.69) | ITGB1ITGA4MEN1KMT2AKDM1A | |
| SCHEMBL2432856 | 0.94 | ITGB1 (0.80) | ITGB1ITGA4 | |
| SCHEMBL2432751 | 0.94 | ITGB1 (0.80) | ITGB1ITGA4 | |
| Water SCHEMBL1170415 | 0.93 | ITGB1 (0.61) | ITGB1ITGA4MEN1KMT2AKDM1A | |
| Bicarbonate SCHEMBL2438579 | 0.93 | ITGB1 (0.60) | ITGB1ITGA4MEN1KMT2AKDM1A | |
| SCHEMBL2430237 | 0.88 | ITGB1 (0.71) | ITGB1ITGA4MEN1KMT2AKDM1A | |
| SCHEMBL2432788 | 0.88 | ITGB1 (0.71) | ITGB1ITGA4MEN1KMT2AKDM1A | |
| SCHEMBL2431888 | 0.83 | ITGB1 (0.82) | ITGB1ITGA4 | |
| SCHEMBL2432914 | 0.83 | ITGB1 (0.79) | ITGB1ITGA4 | |
| SCHEMBL2433299 | 0.82 | ITGB1 (1.00) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | claimed |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | TOHOKU UNIVERSITY (JP) | 2021-10-19 | — | — | US | disclosed |
| US-10463647-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20190224165-A1 | Agent for Preventing or Ameliorating Hearing Impairment | TOHOKU UNIVERSITY (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20180353475-A1 | Erythropoietin Expression Promoter | KAKE EDUCATIONAL INSTITUTION (JP) | 2018-12-13 | — | — | US | disclosed |
| US-10004718-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2018-06-26 | — | — | US | disclosed |
| WO-2017072816-A1 | THERAPEUTIC AGENT FOR FIBROTIC DISEASES OF THE ORGANS | 国立大学法人東北大学 | 2017-05-04 | — | — | WO | disclosed |
| US-20150353489-A1 | Erythropoietin Expression Promoter | KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION KANAGAWA CHILDREN'S MEDICAL CENTER (JP) | 2015-12-10 | — | — | US | disclosed |
| WO-2014080640-A1 | ERYTHROPOIETIN EXPRESSION PROMOTER | 国立大学法人東北大学 (JP) | 2014-05-30 | — | — | WO | disclosed |
| US-20120258093-A1 | VLA-4 AS A BIOMARKER FOR PROGNOSIS AND TARGET FOR THERAPY IN DUCHENNE MUSCULAR DYSTROPHY | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-10-11 | — | — | US | disclosed |
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7893279-B2 | Cyclohexanecarboxylic acid compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-02-22 | — | — | US | disclosed |
| US-7691894-B2 | Cyclohexanecarboxylic acid compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20100022783-A1 | CYCLOHEXANECARBOXYLIC ACID COMPOUND | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20070105936-A1 | Cyclohexanecarboxylic acid compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180353475-A1 | Erythropoietin Expression Promoter | EPOR, NFE2L2, FOXO1 | ITGB1 3148/4885ITGA4 3410/4885MEN1 3086/4885 |
| US-20070105936-A1 | Cyclohexanecarboxylic acid compound | VCAM1, CLIC4, PLAAT4 | ITGB1 483/4885ITGA4 17/4885MEN1 2678/4885 |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | SLC26A4, OTC, SLC25A20 | ITGB1 4494/4885ITGA4 4489/4885MEN1 1339/4885 |
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | ITGB1 5/4885ITGA4 4/4885MEN1 1582/4885 |
| US-20150353489-A1 | Erythropoietin Expression Promoter | EPOR, NFE2L2, FOXO1 | ITGB1 3148/4885ITGA4 3410/4885MEN1 3086/4885 |
| US-20100022783-A1 | CYCLOHEXANECARBOXYLIC ACID COMPOUND | VCAM1, CLIC4, PLAAT4 | ITGB1 483/4885ITGA4 17/4885MEN1 2678/4885 |
| US-20190224165-A1 | Agent for Preventing or Ameliorating Hearing Impairment | SLC26A4, OTC, SLC25A20 | ITGB1 4494/4885ITGA4 4489/4885MEN1 1339/4885 |
| US-10004718-B2 | Erythropoietin expression promoter | EPOR, NFE2L2, FOXO1 | ITGB1 3148/4885ITGA4 3410/4885MEN1 3086/4885 |
| US-10463647-B2 | Erythropoietin expression promoter | EPOR, NFE2L2, FOXO1 | ITGB1 3148/4885ITGA4 3410/4885MEN1 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.